Nikitha M. Das

Nikitha M. Das

Auto-generated profile, based on publicly available information

Nikitha M. Das

The University of Texas Southwestern Medical Center, Dallas, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2024 in Cancer Research
Verified
Journal Article
Closed access
PDF file
MMMauricio Marquez-Palencia
Mauricio Marquez-Palencia
LHLuis Reza Herrera
Luis Reza Herrera
PPPravat Kumar Parida
Pravat Kumar Parida
SGSuvranil Ghosh
Suvranil Ghosh
KKKangsan Kim
Kangsan Kim
SMSrinivas Malladi
Srinivas Malladi
Therapy resistance and metastatic progression are primary causes of cancer-related mortality. Disseminated tumor cells possess adaptive traits that enable them to reprogram their metabolism, maintain stemness, and resist cell death, facilitating their persistence to drive recurrence. The survival of disseminated tumor cells also depends on their ability to modulate replication stress in response to therapy while colonizing inhospitable microenvironments. In this study, we discovered that the nuclear translocation of AXL, a TAM receptor tyrosine kinase, and its interaction with WRNIP1, a DNA replication stress response factor, promotes the survival of HER2+ breast cancer cells that are resistant to HER2-targeted therapy and metastasize to the brain. In preclinical models, knocking down or pharmacologically inhibiting AXL or WRNIP1 attenuated protection of stalled replication forks. Furthermore, deficiency or inhibition of AXL and WRNIP1 also prolonged metastatic latency and delayed relapse. Together, these findings suggest that targeting the replication stress response, which is a shared adaptive mechanism in therapy-resistant and metastasis-initiating cells, could reduce metachronous metastasis and enhance the response to standard-of-care therapies. Significance: Nuclear AXL and WRNIP1 interact and mediate replication stress response, promote therapy resistance, and support metastatic progression, indicating that targeting the AXL/WRNIP1 axis is a potentially viable therapeutic strategy for breast cancer.

29 August 2025 in Cancer Research
Verified
Journal Article
Open access
LALeanne G. Ahronian
Leanne G. Ahronian
SSSoumyadip Sahu
Soumyadip Sahu
MZMinjie Zhang
Minjie Zhang
APAyushi S. Patel
Ayushi S. Patel
KGKe Geng
Ke Geng
KWKwok-Kin Wong
Kwok-Kin Wong
Non-small cell lung cancer (NSCLC) patients with loss of the tumor suppressor gene STK11 are resistant to immune checkpoint therapies like anti-PD-1. Here, we conducted an in vivo CRISPR screen that identified HDAC1 as a target to reverse anti-PD-1 resistance driven by loss of STK11 and developed TNG260, a potent small-molecule inhibitor of the CoREST complex with selectivity exceeding previously generated inhibitors in this class in preclinical studies. Treatment with TNG260 led to increased expression of immunomodulatory genes in STK11-deficient cancer cells. When combined with anti-PD-1, TNG260 induced immune-mediated stasis and/or regression in STK11-deficient syngeneic tumor models and autochthonous NSCLC models. In the tumors of patients with STK11-deficient cancers on a clinical trial (NCT05887492), treatment with a combination of TNG260 and pembrolizumab increased intratumoral histone acetylation, PD-L1 tumor proportion scores, and T cell infiltration into the tumor microenvironment. This study illustrates a promising treatment strategy for addressing immune evasion in STK11-mutant NSCLC patients.

25 January 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
LMLauren Catherine M. Martires
Lauren Catherine M. Martires
LALeanne G. Ahronian
Leanne G. Ahronian
CPCharlotte B. Pratt
Charlotte B. Pratt
NDNikitha M. Das
Nikitha M. Das
XZXiaobin Zhang
Xiaobin Zhang
HNHilary E. Nicholson
Hilary E. Nicholson
Synthetic lethality approaches in BRCA1/2-mutated cancers have focused on PARP inhibitors, which are subject to high rates of innate or acquired resistance in patients. In this study, we used CRISPR/Cas9-based screening to identify DNA ligase I (LIG1) as a novel target for synthetic lethality in BRCA1-mutated cancers. Publicly available data supported LIG1 hyperdependence of BRCA1 mutant cells across a variety of breast and ovarian cancer cell lines. We used CRISPRn, CRISPRi, RNAi, and protein degradation to confirm the lethal effect of LIG1 inactivation at the DNA, RNA, and protein level in BRCA1 mutant cells in vitro. LIG1 inactivation resulted in viability loss across multiple BRCA1-mutated cell lines, whereas no effect was observed in BRCA1/2 wild-type cell lines, demonstrating target selectivity for the BRCA1 mutant context. On-target nature of the phenotype was demonstrated through rescue of viability with exogenous wild-type LIG1 cDNA. Next, we demonstrated a concentration-dependent relationship of LIG1 protein expression and BRCA1 mutant cell viability using a titratable, degradable LIG1 fusion protein. BRCA1 mutant viability required LIG1 catalytic activity, as catalytically dead mutant LIG1K568A failed to rescue viability loss caused by endogenous LIG1 depletion. LIG1 perturbation produced proportional increases in PAR staining in BRCA1 mutant cells, indicating a mechanism consistent with the function of LIG1 in sealing ssDNA nicks. Finally, we confirmed LIG1 hyperdependence in vivo using a xenograft model in which LIG1 loss resulted in tumor stasis in all mice. Our cumulative findings demonstrate that LIG1 is a promising synthetic lethal target for development in patients with BRCA1-mutant cancers.

17 June 2026
Verified
Other
Open access
LMLauren Catherine M. Martires
Lauren Catherine M. Martires
LALeanne G. Ahronian
Leanne G. Ahronian
CPCharlotte B. Pratt
Charlotte B. Pratt
NDNikitha M. Das
Nikitha M. Das
XZXiaobin Zhang
Xiaobin Zhang
HNHilary E. Nicholson
Hilary E. Nicholson
LIG1 inactivation is lethal in BRCA1-mutant MDA-MB-436 cells, and is rescued by exogenous expression of wild-type BRCA1. A) Representative colony formation assay (treatment day 14) using DOX-inducible shRNA against LIG1, PLK1 (pan-lethal control), or a control sequence in MDA-MB-436 cells stably infected with cDNA encoding wild-type BRCA1 or a control vector. B) Model validation with Western blotting. C) Western blots assessing LIG1 protein level at assay endpoint.

17 June 2026
Verified
Other
Open access
LMLauren Catherine M. Martires
Lauren Catherine M. Martires
LALeanne G. Ahronian
Leanne G. Ahronian
CPCharlotte B. Pratt
Charlotte B. Pratt
NDNikitha M. Das
Nikitha M. Das
XZXiaobin Zhang
Xiaobin Zhang
HNHilary E. Nicholson
Hilary E. Nicholson
Quantification of western blots for dTAG-mediated LIG1 degradation. MDA-MB-436 cells were engineered to express a CRISPR-resistant LIG1 cDNA fused to either the FKBP12mut (dTAG) degron (degradable) (A) or the FKBP12wt degron (non-degradable) (B), with knockout of endogenous LIG1. Cells were then treated for 4 days with vehicle (DMSO) or the indicated doses of the VHL-targeting PROTAC dTAGv1 and then subject to immunoblotting for LIG1, HA tag, and a loading control. FC, fold-change.

2 April 2025
Verified
Other
Open access
LMLauren Catherine M. Martires
Lauren Catherine M. Martires
LALeanne G. Ahronian
Leanne G. Ahronian
CPCharlotte B. Pratt
Charlotte B. Pratt
NDNikitha M. Das
Nikitha M. Das
XZXiaobin Zhang
Xiaobin Zhang
HNHilary E. Nicholson
Hilary E. Nicholson
LIG1 inactivation is lethal in BRCA1-mutant MDA-MB-436 cells, and is rescued by exogenous expression of wild-type BRCA1. A) Representative colony formation assay (treatment day 14) using DOX-inducible shRNA against LIG1, PLK1 (pan-lethal control), or a control sequence in MDA-MB-436 cells stably infected with cDNA encoding wild-type BRCA1 or a control vector. B) Model validation with Western blotting. C) Western blots assessing LIG1 protein level at assay endpoint.